Abstract: Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and/or delivering cells into an implantable device and aseptically and selectively sealing a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.
Type:
Grant
Filed:
November 20, 2014
Date of Patent:
July 28, 2020
Assignee:
Viacyte, Inc.
Inventors:
Chad Green, Laura Martinson, Erik Olson, Val Anthony Bellora, Leah Elliott, Richard Alexander Grant, Donald Koenig, Giacomo Strollo
Abstract: Disclosed herein are methods for cryopreserving, hibernation and room temperature storage of PEC aggregates, implantable semipermeable devices and the VC combination product.
Type:
Grant
Filed:
October 26, 2017
Date of Patent:
June 30, 2020
Assignee:
ViaCyte, Inc.
Inventors:
Alan Agulnick, Laura Martinson, Evert Kroon, Michael Scott, Chad Green
Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.
Type:
Grant
Filed:
October 2, 2018
Date of Patent:
February 4, 2020
Assignee:
ViaCyte, Inc.
Inventors:
Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Evert Kroon, Emmanuel E. Baetge
Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
Type:
Application
Filed:
September 25, 2019
Publication date:
January 16, 2020
Applicant:
ViaCyte, Inc.
Inventors:
Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
Type:
Grant
Filed:
April 24, 2018
Date of Patent:
December 31, 2019
Assignee:
ViaCyte, Inc.
Inventors:
Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
Type:
Application
Filed:
August 13, 2019
Publication date:
December 12, 2019
Applicant:
ViaCyte, Inc.
Inventors:
Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.
Type:
Application
Filed:
June 18, 2019
Publication date:
November 28, 2019
Applicant:
ViaCyte, Inc.
Inventors:
Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
Type:
Grant
Filed:
October 31, 2018
Date of Patent:
November 5, 2019
Assignee:
ViaCyte, Inc.
Inventors:
Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
Abstract: Disclosed are devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. The devices include a non-woven fabric external to a cell-excluding membrane, and the non-woven fabric and/or cell-excluding membrane can be perforated. Treatment of the host with immunosuppressive reagents, required to inhibit allograft rejection due to perforations in the cell delivery device, does not compromise maturation or function of transplanted pancreatic endoderm cells.
Type:
Application
Filed:
November 10, 2016
Publication date:
October 31, 2019
Applicant:
Viacyte, Inc.
Inventors:
Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
Type:
Grant
Filed:
February 13, 2017
Date of Patent:
September 24, 2019
Assignee:
ViaCyte, Inc.
Inventors:
Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
Type:
Grant
Filed:
July 12, 2017
Date of Patent:
August 27, 2019
Assignee:
ViaCyte, Inc.
Inventors:
Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
Type:
Application
Filed:
May 3, 2019
Publication date:
August 22, 2019
Applicant:
ViaCyte, Inc.
Inventors:
Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
Abstract: The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.
Type:
Application
Filed:
March 11, 2019
Publication date:
July 4, 2019
Applicant:
ViaCyte, Inc.
Inventors:
Laura Martinson, Chad Green, Evert Kroon, Emmanuel Edward Baetge
Abstract: Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed.
Type:
Application
Filed:
November 26, 2018
Publication date:
May 16, 2019
Applicant:
ViaCyte, Inc.
Inventors:
Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
Abstract: The present invention relates to a perforated semi-permeable device comprising, human pancreatic endocrine cells or human PDX1-positive pancreatic endoderm cells contained within a semi-permeable membrane comprising a synthetic material, wherein the synthetic material is polysulfone (PSF), nano-fiber mats, polyimide, tetrafluoroethylene/polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), polyacrylonitrile, polyethersulfone, acrylic resin, cellulose acetate, cellulose nitrate, polyamide, or hydroxylpropyl methyl cellulose (HPMC), a cell encapsulation chamber, and at least one seal that is within the cell encapsulation chamber.
Type:
Grant
Filed:
August 16, 2017
Date of Patent:
April 30, 2019
Assignee:
ViaCyte, Inc.
Inventors:
Laura Martinson, Chad Green, Evert Kroon, Emmanuel Edward Baetge
Abstract: The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells.
Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
Type:
Application
Filed:
October 31, 2018
Publication date:
February 21, 2019
Applicant:
ViaCyte, Inc.
Inventors:
Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.
Type:
Application
Filed:
October 2, 2018
Publication date:
January 31, 2019
Applicant:
ViaCyte, Inc.
Inventors:
Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Evert Kroon, Emmanuel E. Baetge